Novel Quality Control Metric for the Pharmacotherapy of Major Depressive Disorder: Measuring Guideline Concordance and Its Impact on Symptom Severity

References (58)

1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. IHME, University of Washington. Published 2020. Accessed March 26, 2023. https://vizhub.healthdata.org/gbd-compare
2. Hammer-Helmich L, Haro JM, Jönsson B, et al. Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatr Dis Treat. 2018;14:239–249. PubMed CrossRef
3. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–665. PubMed CrossRef
4. Severe J, Greden JF, Reddy P. Consequences of recurrence of major depressive disorder: is stopping effective antidepressant medications ever safe? Focus Am Psychiatr Publ. 2020;18(2):120–128. PubMed CrossRef
5. Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. PubMed CrossRef
6. Saragoussi D, Touya M, Haro JM, et al. Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatr Dis Treat. 2017;13:2151–2165. PubMed CrossRef
7. Carrasco JL, Kornstein SG, McIntyre RS, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016;31(3):134–146. PubMed CrossRef
8. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663–1672. PubMed CrossRef
9. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677–688. PubMed CrossRef
10. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. PubMed CrossRef
11. Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97–106. PubMed CrossRef
12. Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66. PubMed CrossRef
13. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
14. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161–175. PubMed CrossRef
15. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189–198. PubMed CrossRef
16. Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004;56(1):46–53. PubMed CrossRef
17. Hengartner MP. How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychopharmacol. 2020;10:2045125320921694. PubMed CrossRef
18. Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826. PubMed CrossRef
19. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200. PubMed CrossRef
20. Lundberg J, Cars T, Lööv SÅ, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiatry. 2023;80(2):167–175. PubMed CrossRef
21. Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry. 2016;15(3):228–235. PubMed CrossRef
22. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry. 2010;167(12):1445–1455. PubMed CrossRef
23. Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001;286(23):3003–3004. PubMed CrossRef
24. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMed CrossRef
25. van Bronswijk SC, DeRubeis RJ, Lemmens LHJM, et al. Precision medicine for long-term depression outcomes using the Personalized Advantage Index approach: cognitive therapy or interpersonal psychotherapy? Psychol Med. 2021;51(2):279–289. PubMed CrossRef
26. Cipriani A, Geddes J. Predicting treatment outcome in depression: so far, so good. Lancet Psychiatry. 2016;3(3):192–194. PubMed CrossRef
27. Deshauer D, Moher D, Fergusson D, et al. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ. 2008;178(10):1293–1301. PubMed CrossRef
28. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260. PubMed CrossRef
29. Driessen E, Hollon SD, Bockting CLH, et al. Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? a systematic review and meta-analysis of US National Institutes of Health-funded trials. PLoS One. 2015;10(9):e0137864. PubMed CrossRef
30. Gabriel FC, de Melo DO, Fráguas R, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS One. 2020;15(4):e0231700. doi:10.1371/journal.pone.0231700
31. Zafra-Tanaka JH, Goicochea-Lugo S, Villarreal-Zegarra D, et al. Characteristics and quality of clinical practice guidelines for depression in adults: a scoping review. BMC Psychiatry. 2019;19(1):76. PubMed CrossRef
32. Malmivaara A. Generalizability of findings from randomized controlled trials is limited in the leading general medical journals. J Clin Epidemiol. 2019;107:36–41. PubMed CrossRef
33. Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(8):1276–1280. PubMed CrossRef
34. van der Lem R, de Wever WW, van der Wee NJ, et al. The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice. BMC Psychiatry. 2012;12(1):192. PubMed CrossRef
35. von Wolff A, Jansen M, Hölzel LP, et al. Generalizability of findings from efficacy trials for chronic depression: an analysis of eligibility criteria. Psychiatr Serv. 2014;65(7):897–904. PubMed CrossRef
36. Duhoux A, Fournier L, Menear M. Quality indicators for depression treatment in primary care: a systematic literature review. Curr Psychiatry Rev. 2011;7(2):104–137. CrossRef
37. Setkowski K, Boogert K, Hoogendoorn AW, et al. Guidelines improve patient outcomes in specialised mental health care: a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144(3):246–258. PubMed CrossRef
38. Fortney J, Rost K, Zhang M, et al. The relationship between quality and outcomes in routine depression care. Psychiatr Serv. 2001;52(1):56–62. PubMed CrossRef
39. Hepner KA, Rowe M, Rost K, et al. The effect of adherence to practice guidelines on depression outcomes. Ann Intern Med. 2007;147(5):320–329. https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17785487 PubMed CrossRef
40. Sewitch MJ, Blais R, Rahme E, et al. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use. Can J Psychiatry. 2007;52(3):191–200. PubMed CrossRef
41. Simon GE, Von Korff M, Rutter CM, et al. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58(4):395–401. PubMed CrossRef
42. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. impact on depression in primary care. JAMA. 1995;273(13):1026–1031. PubMed CrossRef
43. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMed CrossRef
44. Saunders EFH, Brady M, Mukherjee D, et al. Gender differences in transdiagnostic domains and function of adults measured by DSM-5 assessment scales at the first clinical visit: a cohort study. BMC Psychiatry. 2023;23(1):709. PubMed CrossRef
45. Gomaa H, Baweja R, Mukherjee D, et al. Transdiagnostic and functional predictors of depression severity and trajectory in the Penn State Psychiatry Clinical Assessment and Rating Evaluation System (PCARES) registry. J Affect Disord. 2022;298(Pt A):86–94. PubMed CrossRef
46. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(suppl E1):e04. PubMed CrossRef
47. Wang HR, Bahk WM, Seo JS, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci. 2017;15(3):199–209. PubMed CrossRef
48. American Psychiatric Association. Practice Guideline For the Treatment of Patients With Major Depressive Disorder. Published November 2010. Accessed August 24, 2023. https://psychiatryonline.org/guidelines
49. Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152. PubMed CrossRef
50. Malmivaara A. Methodological considerations of the GRADE method. Ann Med. 2015;47(1):1–5. PubMed CrossRef
51. Yang L, Su Y, Dong S, et al. Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China. Front Pharmacol. 2022;13:954973. PubMed CrossRef
52. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. PubMed CrossRef
53. Kroenke K, Spitzer RL, Williams JBW, et al. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–359. PubMed CrossRef
54. The Center for Rural Pennsylvania. Rural-Urban Definitions. Published 2020. https://www.rural.pa.gov/data/rural-urban-definitions
55. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed CrossRef
56. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32(12):2479–2489. PubMed CrossRef
57. Herzog DP, Wagner S, Ruckes C, et al. Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017;267(8):711–721. PubMed CrossRef
58. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMed CrossRef